HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CD4 (CD4 Molecule)

BRCA2 mutation • BRCA1 mutation • HER-2 negative • HER-2 negative + HR negative • HER-2 negative + HR negative + BRCA mutation

PD-L1 IHC 22C3 pharmDx • Prosigna® Breast Risk of Recurrence (ROR) Test

carboplatin • gemcitabine • nadunolimab (CAN04)

22d

The Impact of Androgen Receptor Expression on Neoadjuvant Therapy in HER2-Positive Breast Cancer. (PubMed, Breast Cancer (Dove Med Press))

Higher AR expression was associated with improved neoadjuvant treatment response in HER2-positive breast cancer, particularly in the hormone receptor-negative subgroup. However, given the retrospective single-center design and inconsistent findings in the overall population, the clinical value of AR assessment remains preliminary and requires validation in larger prospective studies.

22 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • AR (Androgen receptor)

HER-2 positive • HER-2 negative • HER-2 expression • HR negative • HER-2 negative + ER positive • HER-2 negative + HR negative • HR negative + HER-2 positive

24d

Clipped Node Pathology as a Guide for Limited Axillary Surgery in Occult Breast Cancer. (PubMed, Ann Surg)

In patients with OBC, pathologic assessment of the clipped node can reflect disease burden in the remaining ALNs. Limited axillary surgery anchored in removal of the clipped node should be considered as a strategy for axillary staging following systemic therapy in selected patients with OBC, primarily those with cN1 or cN2 disease.

24 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2)

HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 negative + HR negative

Ten-year subtype survival and systemic-therapy pathways analysis after breast-cancer recurrence in the LACRN MPBC multicountry cohort study. (PubMed, Lancet Reg Health Am)

Chemotherapy was the first-line regimen in 83 of 162 patients (51%), endocrine monotherapy in 55 of 162 (34%), and trastuzumab-pertuzumab-taxane or cyclin-dependent kinase 4 and 6 inhibitor-based regimens in eight of 162 (5%). 87534309); Center for Global Health at the United States-National Cancer Institute at the National Institutes of Health (contract award No. HHSN2612010000871/NO2-PC-2010-00087); Fogarty International Center, NIH, HHS; and Susan G. Komen for the Cure; in Argentina, Instituto Nacional del Cáncer (Ministry of Health), Fundación Argentina de Nanotecnología, Agencia Nacional de Promoción Científica y Tecnológica, CONICET (Ministry of Science, Technology, and Productive Innovation); Brazil, Ministério da Saúde (Ministry of Health); Chile, Instituto de Salud Pública (Public Health Institute) and Ministerio de Salud (Ministry of Health); and Mexico, Consejo Estatal de Ciencia y Tecnología de Jalisco (COECYTJAL) and Universidad de Sonora (University of Sonora).

1 month ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • CDK4 (Cyclin-dependent kinase 4)

HER-2 positive • HR positive • HER-2 negative • HR negative • HR positive + HER-2 negative • HR positive + HER-2 positive • HER-2 negative + HR negative • HR negative + HER-2 positive

Herceptin (trastuzumab) • Perjeta (pertuzumab)

JK06.1.01: A Phase 1/2, Multicenter, Open Label, Dose Escalation and Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients with Unresectable Locally Advanced or Metastatic Cancer (2024-512421-92-00)

P1/2, N=305, Recruiting, Salubris Biotherapeutics Inc. | N=210 --> 305

1 month ago

Enrollment change

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

HER-2 positive • EGFR mutation • HR positive • HER-2 negative • ALK mutation • ROS1 fusion • ESR1 mutation • HER-2 negative + HR negative • HER-2 negative + HR positive + ESR1 mutation

BNT326-01: A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors (clinicaltrials.gov)

P1/2, N=980, Recruiting, BioNTech SE | N=329 --> 980

1 month ago

Enrollment change • Trial initiation date

HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase)

PD-L1 expression • EGFR mutation • HR positive • BRAF mutation • HER-2 negative • EGFR L858R • HER-2 expression • EGFR exon 19 deletion • ALK rearrangement • PD-L1 expression + HER-2 overexpression • HER-2 negative + HR negative

itraconazole • pumitamig (BNT327) • BNT326

2ms

FAsting-mimicking diet in combination with neoadjuvant Chemo-immunoTherapy for early or locally advanced Triple-Negative breast cancer: the prospective, single-arm, open-lable, phase 2 FACT-TN trial (ChiCTR2600118124)

P2, N=80, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

2 months ago

New P2 trial

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)

HER-2 negative • HER-2 negative + ER positive • HER-2 negative + HR negative

Loqtorzi (toripalimab-tpzi)

2ms

A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)

P2/3, N=446, Not yet recruiting, BeBetter Med Inc

2 months ago

New P2/3 trial

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)

HER-2 negative • HER-2 negative + HR negative

carboplatin • gemcitabine

2ms

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca (clinicaltrials.gov)

P2, N=46, Active, not recruiting, Virginia Commonwealth University | Trial completion date: Mar 2026 --> Mar 2027

2 months ago

Trial completion date • Checkpoint inhibition • IO biomarker

HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)

HR positive • HER-2 negative • HR negative • HER-2 negative + HR negative

Keytruda (pembrolizumab) • carboplatin • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • decitabine

2ms

FACT-TN: FMD and Neoadjuvant Chemo-immunotherapy in TNBC (clinicaltrials.gov)

P2, N=80, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting

2 months ago

Enrollment open

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)

HER-2 negative • HER-2 negative + ER positive • HER-2 negative + HR negative

docetaxel • Loqtorzi (toripalimab-tpzi) • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin